Completed PHASE1 INTERVENTIONAL 8-arm NCT01407276

A Study of Omarigliptin (MK-3102) in Participants With Impaired Renal Function (MK-3102-009)

An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MK-3102 in Patients With Impaired Renal Function

Sponsor: Merck Sharp & Dohme LLC

Conditions Chronic Renal Insufficiency Type 2 Diabetes Mellitus

Interventions Omarigliptin

Updated 9 times since 2017 Last updated: Aug 8, 2018 Started: Aug 8, 2011 Primary completion: Mar 23, 2012 Completion: Mar 23, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Chronic Renal Insufficiency and Type 2 Diabetes Mellitus and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2022 [monthly]

Completed PHASE1
Oct 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jun 2018 — Oct 2018 [monthly]

Completed PHASE1
Aug 2017 — Jun 2018 [monthly]

Completed PHASE1
Feb 2017 — Aug 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.